Gout is a chronic inflammatory disease in which high levels of interleukin-8 (CXCL8), myeloid-related protein 8/myeloid-related protein 14 complex, and an altered proteome are associated with diabetes mellitus and cardiovascular disease

Arthritis and Rheumatology

Volumn 67, Issue 12, 2015, Pages 3303-3313

  Kienhorst, Laura B E ^a   Van Lochem, Ellen ^a   Kievit, Wietske ^b   Dalbeth, Nicola ^c   Merriman, Marilyn E ^d   Phipps Green, Amanda ^d   Loof, Arnoud ^b   Van Heerde, Waander ^b   Vermeulen, Sita ^b   Stamp, Lisa K ^e   Van Koolwijk, Elly ^a   De Graaf, Jacqueline ^b   Holzinger, Dirk ^f   Roth, Johannes ^f   Janssens, Hein J E M ^a,b   Merriman, Tony R ^d   Broen, Jasper C A ^g   Janssen, Matthijs ^a   Radstake, Timothy R D J ^g  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; CALGRANULIN A; CALGRANULIN B; COLCHICINE; CYTOKINE; DIURETIC AGENT; FEBUXOSTAT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; PROTEOME; STEROID; TUMOR NECROSIS FACTOR; IL10 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CONTROL; FEMALE; GOUT; HUMAN; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; AGED; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; CALGRANULIN A; CALGRANULIN B; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; GOUT; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PROTEOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84948436456     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39318     Document Type: Article

References (49)

1. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al., Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-6.
2. Roddy E, Doherty M., Epidemiology of gout. Arthritis Res Ther 2010; 12: 223.
3. Saag KG, Choi H., Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006; 8 Suppl 1: S2.
4. Forbess LJ, Fields TR., The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi. Semin Arthritis Rheum 2012; 42: 146-54.
5. Pui K, Gow PJ, Dalbeth N., Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population. J Rheumatol 2013; 40: 872-6.
6. Juraschek SP, Miller ER III, Gelber AC., Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2011; 63: 1295-306.
7. Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, et al., Female gout: clinical spectrum and uric acid metabolism. Arch Intern Med 1991; 151: 726-32.
8. Choi HK, Curhan G., Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
9. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC., Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol 2008; 19: 2204-10.
10. Feigelson P., The inhibition of xanthine oxidase in vitro by trace amounts of l-ascorbic acid. J Biol Chem 1952; 197: 843-50.
11. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al., Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52.
12. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH., Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008; 168: 1104-10.
13. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al., Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010; 49: 141-6.
14. McNearney T, Baethge BA, Cao S, Alam R, Lisse JR, Westlund KN., Excitatory amino acids, TNF-α, and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol 2004; 137: 621-7.
15. Guerne PA, Terkeltaub R, Zuraw B, Lotz M., Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32: 1443-52.
16. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K., Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991; 34: 894-903.
17. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J., The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. J Clin Endocrinol Metab 2009; 9:2893-9.
18. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C., Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371: 1854-60.
19. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF., Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
20. Van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al., Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med 2014; 370: 433-43.
21. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP., GenePattern 2.0. Nat Genet 2006; 38: 500-1.
22. Wilkins MR, Gasteiger E, Tonella L, Ou K, Tyler M, Sanchez JC, et al., Protein identification with N and C-terminal sequence tags in proteome projects. J Mol Biol 1998; 278: 599-608.
23. Huang DW, Sherman BT, Lempicki RA., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
24. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C., Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 9496-502.
25. Roth J, Teigelkamp S, Wilke M, Grun L, Tummler B, Sorg C., Complex pattern of the myelo-monocytic differentiation antigens MRP8 and MRP14 during chronic airway inflammation. Immunobiology 1992; 186: 304-14.
26. Van den Bos C, Rammes A, Vogl T, Boynton R, Zaia J, Sorg C, et al., Copurification of P6, MRP8, and MRP14 from human granulocytes and separation of individual proteins. Protein Expr Purif 1998; 13: 313-8.
27. Van Bon L, Cossu M, Lof A, Gohar F, van den Berg W, van Heerde W, et al., Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis 2014; 73: 1585-9.
28. Kim SC, Liu J, Solomon DH,. Risk of incident diabetes in patients with gout: a cohort study. Arthritis Rheumatol 2015; 67: 273-80.
29. Singh JA., When gout goes to the heart: does gout equal a cardiovascular disease risk factor? Ann Rheum Dis 2015; 74: 631-4.
30. Remick DG., Interleukin-8. Crit Care Med 2005; 33 Suppl: S466-7.
31. Standiford TJ, Kunkel SL, Basha MA, Chensue SW, Lynch JP III, Toews GB, et al., Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J Clin Invest 1990; 86: 1945-53.
32. Rus HG, Vlaicu R, Niculescu F., Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263-71.
33. Apostolopoulos J, Davenport P, Tipping PG., Interleukin-8 production by macrophages from atheromatous plaques. Arterioscler Thromb Vasc Biol 1996; 16: 1007-12.
34. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K., Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008; 124: 319-25.
35. Panichi V, Taccola D, Rizza GM, Consani C, Ghiadoni L, Filippi C, et al., Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract 2006; 102: c51-8.
36. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al., Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
37. Ma LP, Haugen E, Ikemoto M, Fujita M, Terasaki F, Fu M., S100A8/A9 complex as a new biomarker in prediction of mortality in elderly patients with severe heart failure. Int J Cardiol 2012; 155: 26-32.
38. Baumann M, Schmaderer C, Burkhardt K, Haller B, Heemann U, Dugi K, et al., MRP8/14 is associated with systemic inflammation in stable coronary atherosclerosis in men. Eur J Clin Invest 2011; 41: 1261-7.
39. Yonekawa K, Neidhart M, Altwegg LA, Wyss CA, Corti R, Vogl T, et al., Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis 2011; 218: 486-92.
40. Burkhardt K, Schwarz S, Pan C, Stelter F, Kotliar K, Von Eynatten M, et al., Myeloid-related protein 8/14 complex describes microcirculatory alterations in patients with type 2 diabetes and nephropathy. Cardiovasc Diabetol 2009; 8: 10.
41. Konatalapalli RM, Lumezanu E, Jelinek JS, Murphey MD, Wang H, Weinstein A., Correlates of axial gout: a cross-sectional study. J Rheumatol 2012; 39: 1445-9.
42. Gayen JR, Saberi M, Schenk S, Biswas N, Vaingankar SM, Cheung WW, et al., A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis. J Biol Chem 2009; 284: 28498-509.
43. Poling J, Gajawada P, Lorchner H, Polyakova V, Szibor M, Bottger T, et al., The Janus face of OSM-mediated cardiomyocyte dedifferentiation during cardiac repair and disease. Cell Cycle 2012; 11: 439-45.
44. Gleissner CA, Ley K., CXCL4 in atherosclerosis: possible roles in monocyte arrest and macrophage foam cell formation. Thromb Haemost 2007; 98: 917-8.
45. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
46. Joosten LA, Netea MG, Mylona E, Koenders MI, Malireddi RK, Oosting M, et al., Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010; 62: 3237-48.
47. Schorn C, Janko C, Krenn V, Zhao Y, Munoz LE, Schett G, et al., Bonding the foe-NETting neutrophils immobilize the pro-inflammatory monosodium urate crystals. Front Immunol 2012; 3: 376.
48. Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al., Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623-5.
49. Schauer C, Janko C, Munoz L, Zhao Y, Kienhofer D, Frey B, et al., Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 2014; 20: 511-7.